2021 ASCO Review on Nivo + Ipi vs. Chemo as 1L Treatment for Advance…

Luis Paz-Ares

1L Nivo + Ipi + 2 Cycles of Chemo vs. Chemo Alone (4 Cycles) in mNSC…

Filippo de Marinis

2021 ASCO Update on 1L Nivo + Ipi + 2 Cycles of Chemo vs. Chemo Alon…

Tom John

1L Nivo+Ipi+Chemo for Patients With Advanced NSCLC and Brain Mets: R…

ecancer

D. Carbone

ESMO 2021 Updates on 1L Nivo+Ipi for Unresectable Malignant Pleural …

ecancer

S. Peters

ASCO 2021 Update on IO in NSCLC: Considering Data From the Key Trials

ecancer

L. Raez

2021 ASCO Updates on Lung Cancer: (Neo)adjuvant Therapy, Metastatic …

UAB Medicine Hematology and Oncology Highlights 2021

A. Hegde

Standard 1L Treatment of Advanced NSCLC in 2021: IO Combination & Mo…

Mariam Alexander

Epidemiological Shifts in Lung Cancers: Trends in Treatment and Diag…

Keck School of Medicine of USC Advancing Knowledge in Multidisciplinary Lung Cancer Care

E. David

Serum Proteomic Signature & Advanced NSCLC: Can It Be Used as an Out…

Northwestern Medicine Oncology and Hematology

Y. Chae

Neoadjuvant Treatment of NSCLC With Immune CPIs: Biological Understa…

CECOG Academy

C. Zielinski

USC Updates on RT for mNSCLC: Consolidative Local Therapy

Keck School of Medicine of USC Advancing Knowledge in Multidisciplinary Lung Cancer Care

M. Daly

ASCO 2022 on Clinical and Genomic Characteristics of Pts With Durabl…

ASCO 2022 Conference Coverage

J. Sands

Lecture Summary - ASCO 2022 on Clinical and Genomic Characteristics …

ASCO 2022 Conference Coverage

J. Sands

Lecture Summary - ASCO 2022 on ctDNA Shed as a Tool to Select Immune…

ASCO 2022 Conference Coverage

B. Besse

ASCO 2022 on Immunotherapy Updates in Advanced NSCLC

Nebraska Oncology Society

J. Brahmer

ASCO 2022 3-Year Update From CheckMate 9LA: 1L Nivo + Ipi + 2 Cycles…

ASCO 2022 Conference Coverage

L. Paz-Ares

Lecture Summary - ASCO 2022 3-Year Update From CheckMate 9LA: 1L Niv…

ASCO 2022 Conference Coverage

L. Paz-Ares

Penn Medicine mNSCLC Updates

Penn Medicine Abramson Cancer Center

M. Marmarelis

ASCO 2022 Five-Year Survival Outcomes From CheckMate 227: Nivo + Ipi…

ASCO 2022 Conference Coverage

L. Paz-Ares

Lecture Summary - ASCO 2022 Five-Year Survival Outcomes From CheckMa…

ASCO 2022 Conference Coverage

L. Paz-Ares

ASCO 2022 Early Stage NSCLC Updates

Lung Cancer Europe (LuCE)

J. Naidoo

1L Therapy for Advanced/Metastatic PD-L1 Negative (TPS <1%) NSCLC

Aaron Franke

WCLC 2022 on Modifiable Biomarkers of Response to Immune Checkpoint …

WCLC 2022 Conference Coverage

D. Spakowicz

Lecture Summary - WCLC 2022 on Modifiable Biomarkers of Response to …

WCLC 2022 Conference Coverage

D. Spakowicz

Neoadjuvant vs. Adjuvant Immunotherapy From the Surgeon's Perspective

ILCC 2022 Conference Coverage

T. Mitsudomi

ESMO 2022 on the CheckMate 9LA Study Results: Clinical Outcomes in P…

ESMO 2022 Conference Coverage

T. John

Neoadjuvant Chemotherapy and Immunotherapy for NSCLC

Giuseppe Banna

Neoadjuvant Nivo + Platinum-Doublet Chemo vs. Chemo for Resectable (…

Nicolas Girard